Patient characteristics (N = 46)
| Characteristic . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Age, y | 66 | 48-87 | ||
| Male sex | 27 | 59 | ||
| ECOG performance status | ||||
| 0 | 3 | 7 | ||
| 1 | 41 | 89 | ||
| 2 | 2 | 4 | ||
| Any palpable splenomegaly | 41 | 89 | ||
| Spleen ≥ 5 cm below costal margin | 34 | 74 | ||
| TSS | 32 | 1-84 | ||
| White blood cell count × 109/L | 12 | 2.2-79.8 | ||
| White blood cell count >25 × 109/L | 8 | 17 | ||
| Hemoglobin g/dL | 10.1 | 6.8-16.2 | ||
| Hemoglobin <10 g/dL | 19 | 41 | ||
| PRBC dependency* | 5 | 11 | ||
| Platelet count × 109/L | 271 | 125-1070 | ||
| PB blast ≥1% | 30 | 65 | ||
| BM fibrosis grade† | ||||
| 1 | 4 | 9 | ||
| 2 | 24 | 51 | ||
| 3 | 18 | 39 | ||
| JAK2V617F positive | 24 | 52 | ||
| MPL positive (29 tested) | 2 | 7 | ||
| CALR positive (29 tested) | 5 | 17 | ||
| Abnormal karyotype (45 tested) | 18 | 40 | ||
| Additional molecular mutations by 28-gene panel‡ (30 tested) | 13 | 43 | ||
| High-risk mutations (ASXL1, IDH1/2, EZH2) (30 tested) | 9 | 30 | ||
| DIPSS score | ||||
| Intermediate 1 | 16 | 35 | ||
| Intermediate 2 | 20 | 43 | ||
| High | 10 | 22 |
| Characteristic . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Age, y | 66 | 48-87 | ||
| Male sex | 27 | 59 | ||
| ECOG performance status | ||||
| 0 | 3 | 7 | ||
| 1 | 41 | 89 | ||
| 2 | 2 | 4 | ||
| Any palpable splenomegaly | 41 | 89 | ||
| Spleen ≥ 5 cm below costal margin | 34 | 74 | ||
| TSS | 32 | 1-84 | ||
| White blood cell count × 109/L | 12 | 2.2-79.8 | ||
| White blood cell count >25 × 109/L | 8 | 17 | ||
| Hemoglobin g/dL | 10.1 | 6.8-16.2 | ||
| Hemoglobin <10 g/dL | 19 | 41 | ||
| PRBC dependency* | 5 | 11 | ||
| Platelet count × 109/L | 271 | 125-1070 | ||
| PB blast ≥1% | 30 | 65 | ||
| BM fibrosis grade† | ||||
| 1 | 4 | 9 | ||
| 2 | 24 | 51 | ||
| 3 | 18 | 39 | ||
| JAK2V617F positive | 24 | 52 | ||
| MPL positive (29 tested) | 2 | 7 | ||
| CALR positive (29 tested) | 5 | 17 | ||
| Abnormal karyotype (45 tested) | 18 | 40 | ||
| Additional molecular mutations by 28-gene panel‡ (30 tested) | 13 | 43 | ||
| High-risk mutations (ASXL1, IDH1/2, EZH2) (30 tested) | 9 | 30 | ||
| DIPSS score | ||||
| Intermediate 1 | 16 | 35 | ||
| Intermediate 2 | 20 | 43 | ||
| High | 10 | 22 |
ECOG, Eastern Cooperative Oncology Group; PRBC, packed red blood cells.
PRBC dependency required a transfusion of 2 units PRBCs monthly for 3 months before enrollment.
Bone marrow fibrosis grade per European Myelofibrosis Network grading criteria (Thiele et al17 ).
Patients with 2 molecular mutations (n = 4): TET2 and ASXL1 (n = 1), EZH2 and ASXL1 (n = 1), NRAS and KRAS (n = 1), TET2 and EZH2 (n = 1).